Sutro Biopharma Inc Reports Results for Quarter Ended June 30: Earnings Summary
Sutro Biopharma Inc. reported its financial results for the quarter ended June 30, 2026, highlighting continued progress across its antibody-drug conjugate pipeline alongside a sharp decline in revenue and a wider quarterly loss. The clinical-stage biotechnology company said the period was marked by ongoing development activity, collaboration-driven revenue, and disciplined cost management as it advances key programs toward upcoming milestones.
Quarterly Financial Results
For the quarter ended June 30, Sutro Biopharma posted revenue of $9.8 million, down from $63.7 million in the same period a year earlier. The company said the revenue decline mainly reflected the timing and nature of collaboration-related income, with the current-quarter amount tied principally to the Astellas collaboration.
The company reported a net loss of $38.5 million, compared with a net loss of $11.5 million in the year-ago quarter. On a per-share basis, Sutro posted a loss of $2.33 for the quarter.
Operating Expenses And Cost Trends
Total research and development plus general and administrative expenses were $39.5 million for the quarter, compared with $48.7 million in the prior-year period. The lower expense base reflected the company’s restructuring actions in 2025, including a major workforce reduction and the exit from internal GMP manufacturing.
Despite the reduction in operating costs, Sutro’s bottom line remained pressured by lower collaboration revenue and non-cash interest expense tied to a deferred royalty obligation [web:4]. The company also noted that it continues to focus on balancing development spending with capital efficiency as it moves through clinical and operational milestones.
Pipeline And Business Highlights
During the quarter, Sutro continued to advance its site-specific and novel-format antibody-drug conjugate programs, with management emphasizing execution across clinical and preclinical work. The company highlighted progress in dosing cohorts, safety monitoring, and data generation across its lead programs.
One of the major areas of investor interest is the company’s lead candidate STRO-004, which showed early signs of activity in solid tumors, including partial responses in head and neck, non-small cell lung, and pancreatic cancers. Sutro said the dose-escalation portion of the program was completed ahead of schedule, setting the stage for future expansion work.
Liquidity And Balance Sheet
As of June 30, 2026, Sutro had $54.3 million in cash and cash equivalents and $110.0 million in marketable securities, for total unrestricted liquidity of $164.3 million. That compares with $202.6 million at March 31, 2026, showing a decline in cash resources during the quarter.
The company said its liquidity is expected to support operations into at least the second quarter of 2028. Sutro also reported total liabilities of $297.8 million, including a $239.1 million deferred royalty obligation, which contributed to a stockholders’ deficit of $103.3 million.
Management Commentary
Management said the company remains focused on advancing its pipeline, strengthening manufacturing and analytical capabilities, and expanding strategic collaborations. Sutro also pointed to the importance of non-dilutive funding opportunities, milestone receipts, and continued clinical execution as it works toward later-stage development.
For biotech investors, the main takeaway is that Sutro remains in a development-heavy phase where clinical data and partner activity matter more than near-term profitability [web:4][web:9]. The company’s operating model continues to depend on a mix of research progress, collaboration funding, and disciplined capital allocation.
Investor Outlook
Looking ahead, investors will likely focus on upcoming clinical updates, potential partnership news, and any additional data from STRO-004 and other pipeline assets. Any positive readout could improve sentiment, while delays or weaker-than-expected results could keep pressure on the stock.
The company’s financial position appears sufficient for the near term, but the combination of a growing accumulated deficit, deferred royalty obligations, and clinical development spending means execution will remain critical. For now, Sutro’s story remains centered on pipeline value creation rather than earnings stability.
FAQ
What did Sutro Biopharma report for the quarter ended June 30?
Sutro reported revenue of $9.8 million, a net loss of $38.5 million, and a loss of $2.33 per share for the quarter ended June 30, 2026.
Why did revenue fall so sharply?
Revenue declined mainly because collaboration-related income was lower in the quarter, with the reported amount tied principally to the Astellas collaboration.
How much cash does Sutro have?
As of June 30, 2026, Sutro had $54.3 million in cash and cash equivalents and $110.0 million in marketable securities, totaling $164.3 million in unrestricted liquidity.
How long can Sutro fund operations?
The company said its current cash position is expected to support operations into at least the second quarter of 2028.
What should investors watch next?
Investors should watch for clinical data updates, partnership developments, and progress in the company’s lead programs, especially STRO-004
Is Sutro profitable?
No. Sutro remains a clinical-stage biotech company and reported a net loss for the quarter ended June 30, 2026.
